GAM Holding AG Grows Position in Amedisys Inc (AMED)

GAM Holding AG lifted its stake in shares of Amedisys Inc (NASDAQ:AMED) by 21.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 9,566 shares of the health services provider’s stock after acquiring an additional 1,704 shares during the period. GAM Holding AG’s holdings in Amedisys were worth $1,195,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Dorsey & Whitney Trust CO LLC acquired a new position in shares of Amedisys during the 3rd quarter valued at $203,000. Itau Unibanco Holding S.A. acquired a new position in shares of Amedisys during the 2nd quarter valued at $149,000. Hsbc Holdings PLC acquired a new position in shares of Amedisys during the 3rd quarter valued at $224,000. Cim LLC acquired a new position in shares of Amedisys during the 3rd quarter valued at $246,000. Finally, Creative Planning acquired a new position in shares of Amedisys during the 3rd quarter valued at $257,000. Institutional investors own 92.39% of the company’s stock.

In other news, Director Jake L. Netterville sold 3,394 shares of the company’s stock in a transaction on Friday, November 16th. The shares were sold at an average price of $122.86, for a total value of $416,986.84. Following the completion of the sale, the director now owns 75,266 shares in the company, valued at approximately $9,247,180.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Christopher Gerard sold 7,892 shares of the company’s stock in a transaction on Friday, November 9th. The stock was sold at an average price of $119.02, for a total transaction of $939,305.84. Following the completion of the sale, the chief operating officer now owns 29,429 shares of the company’s stock, valued at approximately $3,502,639.58. The disclosure for this sale can be found here. Insiders have sold a total of 37,486 shares of company stock valued at $4,449,649 in the last 90 days. 2.60% of the stock is currently owned by company insiders.

Shares of AMED stock opened at $130.30 on Friday. The firm has a market cap of $4.32 billion, a price-to-earnings ratio of 58.96, a price-to-earnings-growth ratio of 2.02 and a beta of 1.29. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.06 and a quick ratio of 1.06. Amedisys Inc has a 12 month low of $49.80 and a 12 month high of $140.91.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Monday, October 29th. The health services provider reported $0.95 EPS for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.18. The business had revenue of $417.34 million during the quarter, compared to analyst estimates of $411.05 million. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. Amedisys’s quarterly revenue was up 11.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.56 EPS. Analysts forecast that Amedisys Inc will post 3.58 EPS for the current year.

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Amedisys in a research report on Thursday, September 13th. They set a “neutral” rating and a $117.00 target price on the stock. BidaskClub downgraded shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 16th. ValuEngine upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 28th. Robert W. Baird boosted their target price on shares of Amedisys from $105.00 to $120.00 and gave the company a “neutral” rating in a research report on Thursday, October 11th. Finally, Bank of America set a $139.00 target price on shares of Amedisys and gave the company a “buy” rating in a research report on Tuesday, September 18th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $107.08.

ILLEGAL ACTIVITY NOTICE: “GAM Holding AG Grows Position in Amedisys Inc (AMED)” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/12/08/gam-holding-ag-grows-position-in-amedisys-inc-amed.html.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Further Reading: Analyst Ratings

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply